Targovax is a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors. Targovax’s lead product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus that has been engineered to selectively infect and replicate in cancer cells. It has been shown to activate the immune system to generate tumor-specific immune responses. ONCOS-102’s targeted path-to-market indication is mesothelioma, where the virus is currently being tested in a randomized phase II trial.
Phase l or ll
Anti-infectives, Antivirals, Immuno-Oncology, Immunotherapy, Oncology
Lilleakerveien 2 C
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Upcoming Company Event Participation
European Biotech Investor Day 2019
New York City,
August 1, 2019
Hamptons CEO Roundtable 2019
August 15, 2019
Stock Market Data
Market Data copyright © 2017 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by